These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7796583)

  • 21. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recent progress in the treatment of ED small cell lung cancer].
    Nokihara H; Ohe Y
    Nihon Rinsho; 2002 May; 60 Suppl 5():480-4. PubMed ID: 12101718
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
    Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
    Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
    Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E
    Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Is small cell lung cancer an orphan disease?].
    Pujol JL
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S22-4. PubMed ID: 16719152
    [No Abstract]   [Full Text] [Related]  

  • 28. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
    Saijo N; Horiike A
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
    Perez-Soler R; Glisson BS; Lee JS; Fossella FV; Murphy WK; Shin DM; Hong WK
    J Clin Oncol; 1996 Oct; 14(10):2785-90. PubMed ID: 8874340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irinotecan in the treatment of small cell lung cancer.
    Masuda N; Fukuoka M
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):187-95. PubMed ID: 12113024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
    Noda K; Nishiwaki Y; Kawahara M; Negoro S; Sugiura T; Yokoyama A; Fukuoka M; Mori K; Watanabe K; Tamura T; Yamamoto S; Saijo N;
    N Engl J Med; 2002 Jan; 346(2):85-91. PubMed ID: 11784874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical studies of topotecan.
    Broom C
    Ann N Y Acad Sci; 1996 Dec; 803():264-71. PubMed ID: 8993520
    [No Abstract]   [Full Text] [Related]  

  • 33. Irinotecan plus cisplatin in small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):39-43. PubMed ID: 12375800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data.
    Hsu CY; Chen CH; Hsu KN; Lu YH
    Biometrics; 2019 Mar; 75(1):133-143. PubMed ID: 30004574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lung cancer].
    Ono A; Yamamoto N
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):367-73. PubMed ID: 17353626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chemotherapy for small cell lung cancer].
    Nakanishi Y; Uchino J
    Nihon Kokyuki Gakkai Zasshi; 2004 May; 42(5):399-403. PubMed ID: 15168456
    [No Abstract]   [Full Text] [Related]  

  • 37. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
    Feld R; Evans WK; Coy P; Hodson I; MacDonald AS; Osoba D; Payne D; Shelley W; Pater JL
    J Clin Oncol; 1987 Sep; 5(9):1401-9. PubMed ID: 3040923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
    Zhou K; Wen F; Zhang P; Zhou J; Zheng H; Sun L; Li Q
    Clin Transl Oncol; 2018 Jun; 20(6):768-774. PubMed ID: 29098555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Camptosar plus cisplatin increase survival in small-cell lung cancer study.
    Oncology (Williston Park); 2000 Sep; 14(9):1294. PubMed ID: 11033827
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.